Publication of pharmaceutical company-sponsored research in medical journals, and its presentation at conferences and meetings, is mostly governed by `publication plans' that extract the maximum amount of scientific and commercial value out of data and analyses through carefully constructed and placed papers. Clinical research is typically performed by contract research organizations, analyzed by company statisticians, written up by independent medical writers, approved and edited by academic researchers who then serve as authors, and the whole process organized and shepherded through to journal publication by publication planners. This paper reports on a conference of an international association of publication planners. It describes and analyzes their work in an ecological framework that relates it to marketing departments of pharmaceutical companies, medical journals and publishers, academic authors, and potential audiences. The medical research described here forms a new kind of corporate science, designed to look like traditional academic work, but performed largely to market products.
Abraham, John (2007) `Drug Trials and Evidence Bases in International Regulatory Context', BioSocieties2: 41-56.
2.
Adis Communications (2006) Available at < www.pharmalive.com/content/supplements/gpms/2004/adis.cfm> (accessed 20 December 2006).
3.
Applbaum, Kalman (2004) The Marketing Era: From Professional Practice to Global Provisioning (New York: Routledge).
4.
Barnett, Antony (2003) `Revealed: How Drug Firms "Hoodwink"Medical Journals', The Observer (7 December).
5.
Berenson, Alex (2005) `Evidence in Vioxx Suits Shows Intervention by Merck Officials', The New York Times (24 April): A-1.
6.
Biagioli, Mario (2003) `Rights or Rewards? Changing Frameworks of Scientific Authorship', in M. Biagioli & P. Galison (eds), Scientific Authorship: Credit and Intellectual Property in Science (New York: Routledge): 253-79.
7.
Bloor, David (1976) Knowledge and Social Imagery ( London: Routledge & Kegan Paul).
8.
Callon, Michel (1986) `Some Elements of a Sociology of Translation: Domestication of the Scallops and the Fishermen of St. Brieuc Bay', in J. Law (ed.), Power, Action and Belief (London: Routledge and Kegan Paul ): 196-233.
9.
Cambrosio, Alberto, Peter Keating, Thomas Schlich & George Weisz (2006) `Regulatory Objectivity and the Generation and Management of Evidence in Medicine', Social Science & Medicine63: 189-99.
10.
Carus Clinical Communications (2007) Available at <www.carusclinical.com> (accessed 29 November 2007).
11.
Collins, H.M. (1991) Changing Order: Replication and Induction in Scientific Practice (Chicago, IL: University of Chicago Press).
12.
Collins, H.M. & Robert Evans (2002) `The Third Wave of Science Studies: Studies of Expertise and Experience', Social Studies of Science32: 235-96.
13.
Complete Healthcare Communication (2006) Available at <www.chcinc.com/> (accessed 20 December 2006).
14.
COPE (2008) Committee on Publication Ethics Guidelines on Good Publication Practice. Available at <www.publicationethics.org.uk/guidelines> (accessed 23 June 2008).
15.
Couzin, Jennifer, Constance Holden & Sei Chong (2006) `Hwang Aftereffects Reverberate at Journals', Science311: 321.
16.
Couzin, Jennifer & Michael Schriber (2006) `Fraud Upends Oral Cancer Field, Casting Doubt on Prevention Trial', Science311: 448-49.
17.
Daemmrich, Arthur (2004) Pharmacopolitics: Drug Regulation in the United States and Germany (Chapel Hill, NC: University of North Carolina Press).
18.
Daston, Lorraine & Peter Galison (1992) `The Image of Objectivity' , Representations40: 83-128.
19.
Elliott, Carl (2004) `Pharma Goes to the Laundry: Public Relations and the Business of Medical Education', Hastings Center Report34(5): 18-23.
20.
Envision Pharma (2006) Available at < www.envisionpharma.com/publicationsPlanning/> (accessed 20 December 2006).
21.
Finucane, T. & C. Boult (2004) `Association of Funding and Findings of Pharmaceutical Research at a Meeting of a Medical Professional Society', Journal of the American Medical Association117: 842-45.
22.
Fishman, Jennifer (2004) `Manufacturing Desire: The Commodification of Female Sexual Dysfunction', Social Studies of Science34(2): 187-218.
23.
Food and Drug Administration (2008) `Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices' (Draft Guidance). Available at <www.fda.gov/oc/op/goodreprint.html> ; (accessed 30 April 2008).
24.
Galison, Peter (2003) `The Collective Author', in M. Biagioli & P. Galison (eds), Scientific Authorship: Credit and Intellectual Property in Science (New York: Routledge): 325-55.
25.
Gardiner-Caldwell Group (2007) Available at <www.thgc-group.com/> ; (accessed 29 November 2007).
26.
Glass, Harold E. & David W. Dalton (2006) `Profiles of Phase IV Investigators and Subsequent Prescribing of the Study Drug', Journal of Pharmaceutical Marketing and Management17: 3-17.
27.
Gøtzsche, Peter C., Asbjørn Hróbjartsson, Helle Krogh Johansson, Mette T. Haahr, Douglas G. Altman & An-Wen Chan (2007) `Ghost Authorship in Industry-initiated Randomised Trials', PLoS Medicine4(1): 47-52.
28.
Greene, Jeremy (2004) `Attention to "Details": Etiquette and the Pharmaceutical Salesman in Postwar America', Social Studies of Science34(2): 271-92.
29.
Ham, Chang Dae, Jong Woo Jun & Hyung-Seok Lee (2008) `How to Reach Consumers in a Market where DTC is Not Allowed', Journal of Medical Marketing8(2): 159-68.
30.
Healy, David (2004) `Shaping the Intimate: Influences on the Experience of Everyday Nerves', Social Studies of Science34(2): 219-45.
31.
Healy, David & Dinah Cattell (2003) `Interface between Authorship, Industry and Science in the Domain of Therapeutics', British Journal of Psychiatry183: 22-27.
32.
Innovex (2007) Available at <www.innovex.com/default.htm> ; (accessed 29 November 2007).
33.
International Committee of Medical Journal Editors (2005) `International Committee of Medical Journal Editors Uniform Requirments for Manuscripts Submitted to Biomedical Journals'. Available at <www.icjme.org> (accessed 30 April 2008).
34.
Kleinman, Daniel Lee (2003) Impure Cultures: University Biology and the World of Commerce (Madison, WI: University of Wisconsin Press).
35.
Knorr Cetina, Karin D. (1981) The Manufacture of Knowledge: An Essay on the Constructivist and Contextual Nature of Science (Oxford: Pergamon Press).
36.
Lakoff, Andrew (2004) `The Anxieties of Globalization: Antidepressant Sales and Economic Crisis in Argentina', Social Studies of Science34: 247-69.
37.
Latour, Bruno (1987) Science in Action: How to Follow Scientists and Engineers through Society (Cambridge, MA: Harvard University Press).
38.
Latour, Bruno (1988) The Pasteurization of France (A. Sheridon & J. Law, trans.) (Cambridge, MA: Harvard University Press).
39.
Lexchin, Joel & D. Light (2006) `Commercial Influence and the Content of Medical Journals', British Medical Journal332: 1444-47.
40.
MacKenzie, Donald A. (1978) `Statistical Theory and Social Interests: A Case Study', Social Studies of Science8: 35-83.
41.
Maine, State of (2005) An Act Regarding Advertising by Drug Manufacturers and Disclosure of Clinical Trials . Available at <http://janus.state.me.us/legis/ros/LOM/lom122nd/9Pub351-400/Pub351-400-83.htm> ; (accessed 30 April 2008).
42.
Marks, Harry M. (1997) The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990 (Cambridge: Cambridge University Press).
43.
Matheson, Alastair (2008) `Corporate Science and the Husbandry of Scientific and Medical Knowledge by the Pharmaceutical Industry', Biosocieties3: 355-82.
44.
Mathews, Anna Wilde (2005) `Ghost Story: At Medical Journals, Writers Paid by Industry Play Big Role; Articles Appear Under Name of Academic Researchers, But They Often Get Help; J&J Receives a Positive "Spin"', Wall Street Journal (13 December): A1.
McGoey, Linsey (2007) `On the Will to Ignorance in Bureaucracy', Economy and Society36(2): 212-35.
47.
Medical News Today (2005) `80% of Pharmaceutical Medical Publications Spending Outsourced in 2004', Medical News Today (7 March).
48.
Mercer, David (2002) `Scientific Method Discourses in the Construction of "EMF Science": Interests, Resources and Rhetoric in Submissions to a Public Inquiry', Social Studies of Science32: 205-33.
49.
Metlay, Grischa (2006) `Reconsidering Renormalization: Stability and Change in 20th-Century Views on University Patents', Social Studies of Science36(4): 565-98.
50.
Mirowski, Philip & Robert Van Horn (2005) `The Contract Research Organization and the Commercialization of Scientific Research', Social Studies of Science35: 503-34.
51.
Moffatt, Barton & Carl Elliott (2007) `Ghost Marketing: Pharmaceutical Companies and Ghostwritten Journal Articles', Perspectives in Biology and Medicine50(1): 18-31.
52.
Moynihan, Ray & Alan Cassels (2005) Selling Sickness: How the World's Biggest Pharmaceutical Companies are Turning Us All into Patients (Vancouver: Greystone Books).
53.
Moynihan, Ray & David Henry (2006) `The Fight against Disease Mongering: Generating Knowledge for Action', PLoS Medicine3(4): e191.
54.
Oldani, Michael (2004) `Thick Prescriptions: Toward an Interpretation of Pharmaceutical Sales Practices', Medical Anthropology Quarterly18: 325-56.
55.
Patsopoulos, Nikolaos, John P.A. Ioannidis & A. Analatos Apostolow (2006) `Origin and Funding of the Most Frequently Cited Papers in Medicine: Database Analysis', British Medical Journal332: 1061-64.
56.
Petersen, Melody (2008) Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs (New York: Farrar, Straus & Giroux).
57.
Pickering, Andrew (1984) Constructing Quarks: A Sociological History of Particle Physics (Chicago, IL: University of Chicago Press).
58.
Porter, Theodore M. (1995) Trust in Numbers: The Pursuit of Objectivity in Science and Public Life (Princeton, NJ: Princeton University Press).
59.
Psaty, Bruce M. & Richard A. Kronmal (2008) `Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment', Journal of the American Medical Association299(15): 1813-17.
60.
Rasmussen, Nicolas (2005) `The Drug Industry and Clinical Research in Interwar America: Three Types of Physician Collaborator', Bulletin of the History of Medicine79: 50-80.
61.
Ross, Joseph S., Kevin P. Hill, David S. Egilman & Harlan M. Krumholz (2008) `Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation', Journal of the American Medical Association299(15): 1800-12.
62.
Shapin, Steven (1979) `The Politics of Observation: Cerebral Anatomy and Social Interests in the Edinburgh Phrenology Disputes', in R. Wallis (ed.), On the Margins of Science: The Social Construction of Rejected Knowledge (Keele: University of Keele):139-78.
63.
Sismondo, Sergio (2007) `Ghost Management: How Much of the Medical Literature is Shaped Behind the Scenes by the Pharmaceutical Industry?', PLoS Medicine4(9): e286.
64.
Slaughter, Sheila, Teresa Campbell, Margaret Holleman & Edward Morgan (2002) `The "Traffic" in Graduate Students: Graduate Students as Tokens of Exchange between Academe and Industry' , Science, Technology, & Human Values27: 282-312.
65.
Smith, Richard (2006) `Lapses at the New England Journal of Medicine' , Journal of the Royal Society of Medicine99(8): 380-82.
66.
Sox, Harold & Drummond Rennie (2006) `Research Misconduct, Retraction, and Cleansing the Medical Literature: Lessons from the Poehman Case', Annals of Internal Medicine144: 609-13.
67.
Steinman, Michael A., Lisa A. Bero, Mary-Margaret Chren & C. Seth Landefeld (2006) `Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents', Annals of Internal Medicine145(4): 284-93.
68.
Thomson Scientific Connexions (2006) Available at <www.sciconnex.com/> (accessed 14 December 2006).
69.
Timmermans, Stefan & Marc Berg (2003) The Gold Standard: The Challenge of Evidence-based Medicine and Standardization in Health Care (Philadelphia , PA: Temple University Press).
70.
Turner, Erick H., Annette M. Matthews, Eftihia Linardatos, Robert A. Tell & Robert Rosenthal (2008) `Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy', New England Journal of Medicine358(3): 252-60.
71.
Washington Legal Foundation (2007) Available at < www.wlf.org/> (accessed 29 November 2007).
72.
Watermeadow Medical (2007) Available at <www.watermeadowmedical.com/> ; (accessed 29 November 2007).
73.
Woolgar, Steve (1981) `Interests and Explanation in the Social Study of Science', Social Studies of Science11: 365-94.
74.
World Health Organization (2004) `The World Medicines Situation'. Available at < www.who.int/medicinedocs/collect/medicinedocs/pdf/s6160e/s6160e.pdf> ; (accessed 30 April 2008).
75.
Ylikoski, Petri (2004) `Interests, Folk Psychology, and the Sociology of Scientific Knowledge', Philosophical Explorations7(3): 265-79.
